Novartis Has High Hopes For Tasigna And Predicts It Could Outpace Gleevec In CML
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis execs are "pleased" with Tasigna's safety profile in a head-to-head study against the more lucrative CML therapy, Gleevec.